2,335 Shares in Boston Scientific Corporation $BSX Bought by Convergence Financial LLC

Convergence Financial LLC purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,335 shares of the medical equipment provider’s stock, valued at approximately $251,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC grew its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares in the last quarter. D.A. Davidson & CO. lifted its position in shares of Boston Scientific by 4.6% in the 1st quarter. D.A. Davidson & CO. now owns 11,536 shares of the medical equipment provider’s stock worth $1,164,000 after acquiring an additional 504 shares during the period. Concurrent Investment Advisors LLC lifted its position in shares of Boston Scientific by 36.0% in the 1st quarter. Concurrent Investment Advisors LLC now owns 13,245 shares of the medical equipment provider’s stock worth $1,336,000 after acquiring an additional 3,509 shares during the period. Penserra Capital Management LLC increased its position in shares of Boston Scientific by 128.3% during the first quarter. Penserra Capital Management LLC now owns 8,811 shares of the medical equipment provider’s stock valued at $888,000 after purchasing an additional 4,952 shares during the period. Finally, Financial Counselors Inc. increased its position in shares of Boston Scientific by 63.5% during the first quarter. Financial Counselors Inc. now owns 12,048 shares of the medical equipment provider’s stock valued at $1,215,000 after purchasing an additional 4,680 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BSX has been the subject of several research reports. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Leerink Partners raised their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. Wells Fargo & Company upped their target price on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, Truist Financial raised their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Trading Up 0.1%

Shares of Boston Scientific stock opened at $98.91 on Thursday. Boston Scientific Corporation has a 12-month low of $85.03 and a 12-month high of $109.50. The stock has a market capitalization of $146.56 billion, a P/E ratio of 52.89, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a 50-day simple moving average of $100.34 and a 200 day simple moving average of $102.43. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ellen M. Zane sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $102.24, for a total value of $296,598.24. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,467,460.16. The trade was a 10.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 162,891 shares of company stock worth $16,475,387. 0.50% of the stock is owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.